Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 10/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | GRK5 | P34947 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239384 | 0.86 | ALDH1A1 (0.44) | CYP11B1CYP11B2FYNPDE10ABTK | |
| SCHEMBL238212 | 0.83 | KDM4E (0.37) | CYP11B1CYP11B2FYNPDE10ABTK | |
| SCHEMBL236731 | 0.81 | RAB9A (0.39) | NPC1RAB9AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL239178 | 0.81 | ALDH1A1 (0.37) | CYP11B1CYP11B2FYNGRK5KDM4E | |
| SCHEMBL239636 | 0.80 | DRD2 (0.36) | CYP11B1CYP11B2FYNPDE10ABTK | |
| SCHEMBL2755267 | 0.79 | PIM1 (0.41) | CYP11B1CYP11B2FYNGRK5NPC1 | |
| SCHEMBL240104 | 0.79 | PIK3CD (0.35) | BTKNPC1RAB9AL3MBTL1 | |
| SCHEMBL236682 | 0.76 | KDM5B (0.38) | FYNLRRK2PDE10ABTKKDM4E | |
| SCHEMBL238460 | 0.74 | AKT1 (0.38) | — | |
| SCHEMBL2755280 | 0.74 | AKT1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406250-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2406250-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8614221-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3R5 | CYP11B1 2800/4885CYP11B2 3571/4885FYN 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.